Protalix is a publicly traded biotechnology company (AMEX: PLX), that is producing recombinant therapeutic proteins through the ProCellEx™ plant cell system.



LATEST NEWS   <GO TO PRESS ROOM>
07/31/08 Protalix BioTherapeutics to Present at the Oppenheimer Small and Mid Cap Clinical and Regulatory Conference
07/01/08 Protalix BioTherapeutics Joins the Russell Microcap(TM) Index
06/03/08 Protalix BioTherapeutics to Initiate an Double Blind Extension Study for the Phase III Clinical Trial of prGCD
05/23/08 Protalix BioTherapeutics to Present at Three International Healthcare Conferences and ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting
04/08/08 Protalix BioTherapeutics Receives Research Grant from the Office of the Chief Scientist of Israel's Ministry of Industry and Trade
02/12/08 Protalix BioTherapeutics Appoints Professor Roger D. Kornberg to Board of Directors
01/22/08 Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
01/14/08 Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
PROTALIX BIOTHERAPEUTICS

2 Snunit St., Science Park,
POB 455, Karmiel 20100, Israel.

T:   +972-4-9028100
F:   +972-4-988-9489
E:   
      
© 2007 Protalix Biotherapeutics. All Rights Reserved.